

1 **Supporting Information**

2

3 **Title:** Microglia mediate contact-independent neuronal network remodeling via secreted Neuraminidase-3  
4 associated with extracellular vesicles

5

6 **Authors:** Corleone S. Delaveris,<sup>1</sup> Catherine L. Wang,<sup>1</sup> Nicholas M. Riley,<sup>1</sup> Sherry Li,<sup>1</sup> Rishikesh U. Kulkarni,<sup>1‡</sup>  
7 Carolyn R. Bertozzi<sup>1,2‡</sup>

8

9 **Affiliations:**

10 <sup>1</sup>Stanford University, Department of Chemistry and Sarafan ChEM-H, Stanford, CA 94305, USA

11 <sup>2</sup>Howard Hughes Medical Institute, Stanford, CA 94305 USA

12 ‡To whom correspondence should be addressed: rishi@kulkarni.science; [bertozzi@stanford.edu](mailto:bertozzi@stanford.edu)

13

14

## 15 **Materials and Methods.**

### 16 **Cell culture**

17 BV2 murine microglia (a kind gift from T. Wyss-Coray) were propagated in DMEM supplemented with 10%  
18 hiFBS. Microglia were maintained at a low passage number (< 10 since obtaining initial stocks) and split at or  
19 before ~ 70% confluency to avoid runaway inflammation as caused by dead or floating BV2 cells. If cells grew  
20 overconfluent, the culture was discarded. Typically, ~ 1e6 microglia were seeded in a T75 in 25 mL split every  
21 two days. Microglia were harvested using Gibco enzyme-free dissociation buffer, incubated for 5 min at room  
22 temperature, and lifted with gentle tapping and pipetting. Microglia were diluted in an equal volume of complete  
23 media, counted with a hemocytometer, pelleted by centrifugation (300 rcf, 5 min), and resuspended in  
24 complete media for subculturing.

25  
26 HeLa cells (ATCC CCL-2) were propagated in DMEM supplemented with 10% hiFBS. HeLa cells were  
27 subcultured at a confluence below 80% to avoid overgrowth. Typically, HeLa cells were split 1:5 every two to  
28 three days. HeLa cells were lifted using trypsin and pelleted by centrifugation (300 rcf, 5 min), before  
29 resuspending in fresh media.

### 31 **Preparation of microglia-conditioned media**

32 Low passage and subconfluent BV2 microglia were harvested using Gibco enzyme-free dissociation media,  
33 incubated for 5 min at room temperature, and lifted with gentle tapping and pipetting. Microglia were diluted in  
34 an equal volume of complete media, counted with a hemocytometer, pelleted by centrifugation (300 rcf, 5 min),  
35 and resuspended in NB++ media (PN) for subculturing.

36  
37 Cultures for conditioned media were seeded at 4e4 cells per cm<sup>2</sup> at 2e5 cells per mL. In some cases, microglia  
38 were stimulated with LPS (1 µg/mL). Cells were cultured at 37 °C in 5% CO<sub>2</sub> for 18 h. The media was then  
39 harvested with careful pipetting cleared of floating cells and large debris by centrifugation (500 rcf, 5 min). The  
40 clarified media was then transferred to a clean tube. In some cases, 5-N-acetyl-2,3-dehydro-2-  
41 deoxyneuraminic acid (DANA) was added to 2 mM. An equal volume of conditioned media was then added to  
42 neuronal cultures.

### 44 **Transfection of HeLa cells and conditioning of media**

45 HeLa cells were transfected with plasmids encoding murine Neu3 (wt or the catalytically inactive mutant  
46 Y369F) using Transit2020 according to the manufacturer's protocol. Plasmids were custom ordered from Twist  
47 Biosciences encoding murine Neu3 (wt or Y369F) C-terminally tagged with a short linker (GSGGGSGGGGSG)  
48 followed by a 3xFLAG tag. Constructs were optimized for human codons and cloned into a pCMV vector from  
49 Twist. After 24 h, the cells were washed with OptiMEM and cultured in a low-volume of OptiMEM for an  
50 additional 24 h, at which point conditioned media was harvested and EV's were isolated.

### 52 **Isolation and labeling of extracellular vesicles**

53 Media was prepared as described above in 25 mL of media in a T125 cell culture flask. In some cases, bulk  
54 extracellular vesicles were isolated by concentrating media in a 100 kDa spin-filter. In other cases, exosomes  
55 were specifically isolated from conditioned media using Takara Capturem EV spin columns (Takara, 635723)  
56 according to the manufacturer's instructions.

57  
58 For extracellular vesicle labeling experiments, BV-2 microglia were cultured in T25 flasks in 5 mL of Dulbecco's  
59 modified eagle medium (DMEM; Gibco) and activated overnight with LPS (1 µg/mL). Supernatant was isolated  
60 and incubated with PKH67 dye for 15 minutes at 37 °C following the PKH67GL-1KT kit (Sigma)<sup>19</sup>. Extracellular  
61 vesicles were then isolated as described above and resuspended in Neurobasal media (Gibco) with 1%

62 GlutaMAX and 2% B-27 supplement. Primary hippocampal neurons were treated overnight with dyed EV  
63 preparation and imaged following kit instructions.

#### 64 **GW4869 treatment of microglia**

65 GW4869 (#D1692, Sigma) was dissolved in DMSO to make a stock solution of 0.2 mg/mL. For inhibition of  
66 exosome generation, BV-2 microglia were treated for 3  $\mu$ M GW4869 for 24 hours before 24-hour LPS  
67 treatment. Culture supernatants were collected for exosome isolation and neuronal treatment.

#### 68 **Periodate labeling of cell surface sialosides**

69  
70 Cells were washed with HBSS solution (Gibco) and then incubated with 1 mM sodium (meta)periodate ( $\text{NaIO}_4$ ;  
71 Sigma) in DPBS (Sigma) for 30 minutes on ice. Cells were then washed twice with sodium acetate buffer (pH  
72 4.7) and fixed for 10 minutes in a 1:1 acetate buffer:methanol solution on ice, then fixed for 10 min in pure  
73 methanol. Cells were then washed with sodium acetate buffer and incubated with AlexaFluor 488  
74 hydroxylamine dye (25  $\mu$ M in sodium acetate buffer; Thermo) for 1 hour at 4 Celsius. Imaging was performed  
75 on an Axio Observer Z-1 (Zeiss) equipped with a Spectra-X Light engine LED light (Lumencor), controlled with  
76 Micro-Manager. Images were acquired with a Plan-Apochromat 20x/0.8 air objective (Zeiss) paired with image  
77 capture from the ORCA-Flash4.0 sCMOS camera (sCMOS; Hamamatsu). Dye was excited with cyan LED  
78 470/24 nm) and emission was collected after passing through the Zeiss 90 HE filter set (425/30 nm, 514/30  
79 nm, 592/25 nm, 709/100 nm LP).

#### 80 **Generation of CRISPR KO of mNeu3**

81  
82 Plasmid constructs encoding Cas9 and a sgRNA were prepared in the lentiCRISPRv2 vector according to  
83 published protocols.<sup>1</sup> Guides were selected based on the genome-wide guides described by Bassik and  
84 coworkers.<sup>2</sup> Plasmid-bearing *Stbl3 E. coli* were grown in 50 mL cultures and DNA was extracted and endotoxin  
85 purified by MiraPrep.<sup>3</sup>

86  
87 LentiCRISPRv2 plasmids were packaged in lentiviruses produced from HEK293Ts cotransfected with  
88 pGag/Pol, pRev, pTat, and pVSVG (gift from the Yi-Chang Liu and Jonathan Weismann). In brief, 1.5  $\mu$ g of  
89 LentiCRISPRv2 plasmid were combined with 0.1  $\mu$ g of each packaging plasmid and Lipofectamine LTX  
90 (Thermo Fisher, 15338100) in OptiMEM (Thermo Fisher, 31985062). Transfection complexes were added to  
91 HEK293Ts at 70-80% confluency in a 6 well plate in 2 mL fresh media. The media was aspirated after 12 h  
92 and bleached. After 48 h, the media was harvested and filtered through a 0.45  $\mu$ m syringe filter to afford the  
93 viral supernatants.

94  
95 BV2 cells were resuspended in fresh viral-containing media with polybrene (8  $\mu$ g/mL). Media was changed  
96 after 24 h, and after 72 h antibiotic selection was started (2.5  $\mu$ g/mL). After two weeks of selection, editing of  
97 the target gene was validated by TIDE analysis.<sup>4</sup>

#### 98 **Cytokine release assay**

99  
100 Adherent NEU3 KO and WT BV-2 microglia were plated (100,00 cells/well in a 24-well plate) in Neurobasal  
101 media (Gibco) with 1% GlutaMAX and 2% B-27 supplement one day prior to experiment. Media was treated  
102 with LPS (1  $\mu$ g/mL), LPS + DANA (2  $\mu$ M), or left untreated during plating. Three technical replicates were  
103 made per treatment. After 24 hours, cells were spun down at 500 rcf for 5 minutes to remove debris, and  
104 supernatant was extracted for analysis. Cytokine levels were assessed using the BD Cytometric Bead Array  
105 (CBA) Mouse Inflammation Kit. Flow cytometry was performed on a BD Accuri C6 Plus, and FlowJo software  
106 was used to gate on single cells and live cells for analysis.

108  $\mu$ L

### 109 **Generation of endogenous tagging of mNeu3 by homology-directed recombination**

110 Endogenous tagging of murine Neu3 in BV2 cells was achieved using the Mendenhall-Myers system.<sup>5</sup> In brief,  
111 a pFETCh donor plasmid (Addgene, 63934) containing homology arms for mNeu3 (see table of gene  
112 fragments) was prepared along with PX458 plasmids containing one the only potential target cut site for  
113 mNeu3, as outlined by the target selection described by Mendenhall and Myers. Plasmids were prepared from  
114 50 mL cultures of Stellar *E. coli* and purified by MiraPrep.<sup>3</sup>

115  
116 Low passage BV2 microglia were transfected by magnetofection (OZ Biosciences) according to the  
117 manufacturer's protocols. After 48 h, microglia were treated with a low dose of antibiotic selection (G418,  
118 200X). After two weeks of treatment, only the cells co-transfected with pFETCh donor and PX458 bearing the  
119 sgRNA were alive and growing well in the presence of G418 (0.25 mg/mL). The polyclonal population was  
120 grown out and the genomic DNA was isolated using a GeneJET Genome DNA Purification Kit (Thermo). PCR  
121 was performed using primers +/- 750 bp of the insertion site and compared to PCR products from wt cells. A  
122 clear 2.5 kbp band was observed in addition to a 1.5 kbp band of comparable intensity, indicating (mostly)  
123 monoallelic insertion of the transfer gene.

### 124 **Extracellular vesicles bead capture and analysis by flow cytometry**

125 Immunocapture beads for murine extracellular vesicles were prepared by conjugating polyclonal anti-murine  
126 CD63 (ThermoFisher, PA5-100713) to tosyl-functionalized M450 Dynabeads according to the manufacturer's  
127 protocol for antibody conjugation. After antibody conjugation, the beads were blocked with excess BSA and  
128 quenched in pH 8.5 TBS before use.

129  
130  
131 BV2-conditioned media was cleared by centrifugation (500 rcf, 5 min) and immunocaptured overnight with 2e6  
132 anti-mCD63 beads/mL at 4 °C in a rotating Eppendorf. The beads were magnet captured and washed with  
133 cold 0.1% BSA in PBS. EV-bead complexes were stained at 2e6 beads/mL with antibody solutions for 1 h at  
134 room temperature protected from light. Antibodies were used at the following dilutions: anti-mCD9 clone KMC8  
135 PE conjugate (ThermoFisher 12-0091-81, 1:50); anti-mCD81 clone Eat2 PE conjugate (BD Biosciences  
136 559519, 1:50); anti-FLAG clone D6W5B AlexaFluor 647 conjugate (Cell Signaling Technologies 15009S, 1:50);  
137 rat IgG2a isotype control PE conjugate (BD Biosciences 554689, 1:50); rabbit IgG isotype control AlexaFluor  
138 647 conjugate (ThermoFisher 51-4616-82, 1:50). Beads were magnet captured, washed, resuspended at 1e6  
139 beads/mL and analyzed by flow cytometry on an Accuri C6 flow cytometer. Data were analyzed in FlowJo.  
140 Beads were gated on isotype-treated controls.

### 141 **Quantitative reverse transcriptase PCR analysis**

142 Expression levels of Neu1, Neu3, and Neu4 in murine BV2 microglia and primary murine hippocampal neurons  
143 were evaluated by quantitative RT-PCR (qPCR). Total RNA was isolated by TRIzol reagent extraction  
144 (ThermoFisher, 15596026) and Zymo RNA Clean and concentrator kits (Zymo, R1013) using manufacturer's  
145 protocols. Libraries of cDNA were generated via EcoDry premix kit (Takara, 639542) using 2  $\mu$ g total RNA.  
146 Transcript levels were quantitated via qPCR using SybrGreen master mix (ThermoFisher, 4309155). Transcript  
147 levels were normalized to transcript levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
148

### 149 **Dissociated hippocampal cultures**

150 All animal procedures were approved by Stanford University's Administrative Panel on Laboratory Animal Care  
151 and conformed to the NIH Guide for Care and Use of Laboratory Animals and the Public Health Policy. Primary  
152 hippocampal tissue was harvested from E16.5 C57BL/6 embryonic mice (Charles River) immediately after  
153 sacrifice of the pregnant dam. The isolated hippocampi were dissociated using Papain Dissociation System  
154

155 (Worthington Biochemical Corporation) and trituration with fire-polished Pasteur pipettes. The dissociated cells  
156 were plated onto 12mm coverslips (Chemglass Life Sciences) pre-treated with Poly-D Lysine (PDL; 1 mg/mL,  
157 Sigma-Aldrich) at a density of  $6 \times 10^4$  cells per coverslip. The cells were maintained for 24 hours in Dulbecco's  
158 modified eagle medium (DMEM; Gibco) supplemented with 4.5 g/L D-glucose, 10% FBS, 1% GlutaMAX, and  
159 2% B-27 (Gibco), and then switched to Neurobasal media (Gibco) with 1% GlutaMAX and 2% B-27  
160 supplement. Plates were incubated at 5% CO<sub>2</sub>, 37°C, and subsequent media changes took place every 7  
161 days.

### 162 **Voltage imaging of neurons**

163 Neurons were incubated with an HBSS solution (Gibco) containing BeRST1 (1.0µM; Miller Lab, UC Berkeley)  
164 for 20 minutes at 37°C prior to imaging. Functional imaging of hippocampal cells was performed on an Axio  
165 Observer Z-1 (Zeiss) equipped with a Spectra-X Light engine LED light (Lumencor), controlled with Micro-  
166 Manager. Images were acquired with a Plan-Apochromat 20x/0.8 air objective (Zeiss) paired with image  
167 capture from the ORCA-Flash4.0 sCMOS camera (sCMOS; Hamamatsu) with 4x4 in-camera binning. We used  
168 a sampling rate of 0.5 kHz over 5 or 10 seconds in order to resolve individual action potentials. To achieve  
169 maximum sampling rate, a field of view (FOV) size of 512x100 pixels (665.6x130 µm) was used for  
170 simultaneous recording of 5-15 neurons at a time. BeRST 1 was excited with a 631 nm light (LED; 631nm, 28  
171 nm bandpass) with an LED power of 70%. Emission from BeRST 1 was collected with a 680/10 nm bandpass  
172 emission filter after passing through a dichroic mirror (425/30 nm, 514/30 nm, 592/25 nm, 709/100 nm LP).  
173

### 174 **Image analysis**

175 Analysis of voltage traces in primary neurons was performed using ImageJ and custom Python scripts. All  
176 Python scripts used to analyze data in this study are available at [github.com/rishi-kulkarni/SpykeMapper](https://github.com/rishi-kulkarni/SpykeMapper).  
177 Regions of interest (ROIs) were drawn around cell bodies within a field of view and the average fluorescence  
178 over time was extracted and inputted into an Excel workbook. The fluorescence time course data was then  
179 analyzed using a custom Python script that performed subthreshold trace extraction and spike train generation.  
180 Briefly, the subthreshold activity was identified using asymmetric least squares regression and subtracted from  
181 raw time course data to generate a flattened trace containing a flat baseline and spiking activity. Spikes were  
182 identified from the flattened trace using a threshold of +6 STDEV of all cellular fluorescence values within a  
183 coverslip to generate a digitized spike train containing all-or-nothing firing data or Raster plot. Factor analysis  
184 was performed using the FactoryAnalyzer module with no rotation. The shared variance values per network  
185 were compared using Cohen's d.  
186

### 187 **Preparation of extracellular vesicles for mass spectrometry**

188 Extracellular vesicles were enriched as described above in the section Isolation and labeling of extracellular  
189 vesicles. Enriched EVs were labeled with membrane-impermeable sulfo-NHS-biotin (Thermo Fisher Scientific,  
190 21217) per the manufacturer's protocol. In brief, EVs in pH 8.0 PBS were labeled for 30 min at room  
191 temperature with sulfo-NHS-biotin (2 mM) and were quenched by the addition of 100 mM glycine. EVs  
192 solutions were desalted using spin columns. EVs were lysed by the subsequent addition of 10X RIPA buffer.  
193 Samples were prepared in triplicate, and triplicate control samples were treated equivalently, except sulfo-  
194 NHS-biotin was excluded. All samples were enriched using streptavidin magnetic beads (Pierce, #88817) and  
195 the DynaMag-2 Magnet (Invitrogen, #12321D) based on a protocol adopted from previous work.<sup>6</sup> Buffers were  
196 made fresh, including ETDA buffer (150 mM NaCl, 100 mM Tris pH 8, 0.5 mM EDTA pH 8), urea buffer (2 <  
197 urea, 10 mM Tris) and elution buffer (5% SDS in RIPA, 20 mM DTT, 2 mM biotin). 25 µL of streptavidin beads  
198 were used per sample, and beads were washed with 50 µL of cold RIPA twice before being resuspended in 25  
199 µL cold RIPA. Beads were added to each sample, which were continuously rotated overnight at 4 C. The next  
200 day, the unbound fraction was removed from the beads and kept. Beads were washed with 100 µL RIPA,  
201

202 which was added to the saved unbound fraction (labeled FT, flow through) for each sample. Next, beads were  
203 washed twice with 200  $\mu$ L RIPA, three times with EDTA buffer, three times with 1.5 M NaCl, three times with  
204 0.1 M NaHCO<sub>3</sub>, and once with urea buffer. Proteins were eluted from the beads by boiling at 95 C with 60  $\mu$ L  
205 elution buffer for 10 min. The elution step was repeated, for a total of two elution steps, and elutes from each  
206 step were combined for a given sample. Digestion was performed for eluted and FT proteins using a micro S-  
207 trap protocol provided by the manufacturer (Protifi).<sup>7</sup> For FT samples, proteins were brought to 5% SDS and  
208 reduced with 10 mM DTT for 10 minutes at 95 C. Cysteines were alkylated using 40 mM iodoacetamide for 45  
209 minutes each at room temperature in the dark. The lysate was then acidified with phosphoric acid, brought to  
210 approximately 80-90% methanol with 100 mM TEAB in 90% methanol, and loaded onto the S-trap column.  
211 Following washing with 100 mM TEAB in 90% methanol, trypsin (Promega) was added to the S-trap at a 20:1  
212 protein:protease ratio for 90 minutes at 47 °C. Peptides were eluted in three steps that were collected in the  
213 same tube for a given sample: 40  $\mu$ L of 50 mM TEAB, 40  $\mu$ L 0.2% FA in water, and 40  $\mu$ L of 0.2% FA in 50%  
214 ACN, all spun at 4,000 x g for 1 minute. Eluted peptides were dried via lyophilization.

### 215 216 217 **Preparation of cell-surface labeled neurons for mass spectrometry**

218 Samples were prepared following published cell surface capture protocols that label cell surface proteins  
219 through sialic acids.<sup>8,9</sup> and lysate protein concentrations were quantitated by BCA (Pierce). Lysates were  
220 digested using a mini S-trap protocol (Protifi), which is similar to the micro S-trap protocol above, but with  
221 different volumes. Lysates were brought to 5% SDS and reduced with 5 mM DTT for 5 minutes at 95 C.  
222 Cysteines were alkylated using 25 mM iodoacetamide for 45 minutes each at room temperature in the dark.  
223 Lysates were then acidified with phosphoric acid, brought to approximately 80-90% methanol with 100 mM  
224 TEAB in 90% methanol, and loaded onto the S-trap column. Following washing with 100 mM TEAB in 90%  
225 methanol, trypsin (Promega) was added to the S-trap at a 20:1 protein:protease ratio for 90 minutes at 47 °C.  
226 Peptides were eluted in three steps that were collected in the same tube for a given sample: 80  $\mu$ L of 50 mM  
227 TEAB, 80  $\mu$ L 0.2% FA in water, and 80  $\mu$ L of 0.2% FA in 50% ACN, all spun at 4,000 x g for 1 minute. Eluted  
228 peptides were dried via lyophilization and dried peptides were then resuspended in 100  $\mu$ L 100 mM Tris, pH 8  
229 for enrichment via streptavidin beads (Pierce, #88817) and the DynaMag-2 Magnet (Invitrogen, #12321D).  
230 Buffers were made fresh, including EDTA buffer (150 mM NaCl, 100 mM Tris pH 8, 0.5 mM EDTA pH 8). 50  $\mu$ L  
231 of streptavidin beads were used per sample, and beads were washed with 200  $\mu$ L 100 mM Tris three times  
232 before being resuspended in 400  $\mu$ L 100 mM Tris. Beads were added to each sample (500  $\mu$ L total per  
233 sample), which were continuously rotated overnight at 4 C. The next day, the unbound fraction was removed  
234 from the beads and kept. Beads were washed with 500  $\mu$ L 100 mM Tris, which was added to the saved  
235 unbound fraction (labeled FT, flow through) for each sample. Next, beads were washed five times with 500  $\mu$ L  
236 100 mM Tris, five times with 500  $\mu$ L EDTA buffer, five times with 500  $\mu$ L 1.5 M NaCl, five times with 500  $\mu$ L 0.1  
237 M NaHCO<sub>3</sub>, once with 500  $\mu$ L 80% (v/v) 2-isopropanol, twice with 500  $\mu$ L water, and three times with 500  $\mu$ L  
238 warm (60 °C) 100 mM Tris. Beads were then resuspended in 500  $\mu$ L 100 mM Tris. Glycerol-free PNGaseF  
239 (New England Biolabs, # P0705L) was diluted 2-fold, and 1  $\mu$ L of diluted PNGaseF was added to each set of  
240 beads. Beads with PNGaseF were incubated overnight, where PNGaseF enzymatic cleavage release  
241 formerly N-glycosylated peptides (i.e., de-glycopeptides). Eluted de-glycopeptides were acidified with 10% FA  
242 before desalting with Strata-X reversed phase SPE cartridges (Phenomenex, #8B-S100-AAK) by conditioning  
243 the cartridge with 1 mL ACN followed by 1 mL 0.2% formic acid (FA) in water. Acidified de-glycopeptides  
244 loaded on to the cartridge, followed by a 1 mL wash with 0.2% FA in water. Peptides were eluted with 400  $\mu$ L  
245 of 0.2% FA in 80% ACN and dried via lyophilization.

### 246 247 **Mass spectrometry proteomics LC-MS/MS**

248 All samples were resuspended in 0.2% formic acid in water prior to LC-MS/MS analysis, where half of the  
249 sample was injected for analysis (i.e., 5  $\mu$ L or 10  $\mu$ L total), and non-modified peptides and de-glycopeptides  
250 (referred to collectively as peptides in this section) were analyzed with the same LC-MS/MS method. All  
251 peptide mixtures were separated over a 25 cm EasySpray reversed phase LC column (75  $\mu$ m inner diameter  
252 packed with 2  $\mu$ m, 100 Å, PepMap C18 particles, Thermo Fisher Scientific). The mobile phases (A: water with  
253 0.2% formic acid and B: acetonitrile with 0.2% formic acid) were driven and controlled by a Dionex  $\mu$ Ltimate  
254 3000 RPLC nano system (Thermo Fisher Scientific). An integrated loading pump was used to load peptides  
255 onto a trap column (Acclaim PepMap 100 C18, 5  $\mu$ m particles, 20 mm length, Thermo Fisher Scientific) at 5  
256  $\mu$ L/min, which was put in line with the analytical column 5.5 minutes into the gradient. The gradient increased  
257 from 0% to 5% B between 6 and 6.5 minutes, followed by an increase from 5% to 22% B from 6.5 to 66.5  
258 minutes, an increase from 22% to 90% B from 66.5 to 71 minutes, isocratic flow at 90% B from 71 to 75  
259 minutes, and a re-equilibration at 0% B for 15 minutes for a total analysis time of 90 minutes per injection.  
260 Eluted peptides were analyzed on an Orbitrap Fusion Tribrid MS system (Thermo Fisher Scientific). Precursors  
261 were ionized using an EASY-Spray ionization source (Thermo Fisher Scientific) source held at +2.2 kV  
262 compared to ground, and the column was held at 40 °C. The inlet capillary temperature was held at 275 °C.  
263 Survey scans of peptide precursors were collected in the Orbitrap from 350-1350 Th with an AGC target of  
264 1,000,000, a maximum injection time of 50 ms, and a resolution of 60,000 at 200 m/z. Monoisotopic precursor  
265 selection was enabled for peptide isotopic distributions, precursors of z = 2-5 were selected for data-dependent  
266 MS/MS scans for 2 second of cycle time, and dynamic exclusion was set to 30 seconds with a  $\pm$ 10 ppm  
267 window set around the precursor monoisotope. An isolation window of 1 Th was used to select precursor ions  
268 with the quadrupole. MS/MS scans were collected using HCD at 30 normalized collision energy (nce) with an  
269 AGC target of 100,000 (200%) and a maximum injection time of 54 ms. Mass analysis was performed in the  
270 Orbitrap with a resolution of 30,000 with a first mass set at 120 Th.

## 271 272 **Proteomics data analysis**

273 Peptides from EV labeled data were searched with Morpheus search algorithm<sup>10</sup> housed in the MetaMorpheus  
274 software environment (version 0.0.312)<sup>11</sup> using the entire mouse proteome downloaded from Uniprot<sup>12</sup>  
275 (reviewed, 17030 entries). Cleavage specificity was set to fully tryptic with 2 missed cleavage allowed and a  
276 minimum length of 7 residues, oxidation of methionine was set as a variable modification, and  
277 carbamidomethylation of cysteine was set as a fixed modification. Precursor and product ion tolerances were  
278 set to 5 ppm and 20 ppm, respectively. Output was set to filter at a q-value of 0.01, and FlashLFQ<sup>13</sup> with  
279 matching between runs was enabled. All other parameters were set as default. For quantitative comparisons,  
280 protein intensity values were log<sub>2</sub> transformed prior to further analysis, proteins with greater than three missing  
281 values (i.e., half) per condition were removed, and missing values were imputed from a normal distribution with  
282 width 0.3 and downshift value of 1.8 (i.e., default values) using the Perseus software suite<sup>6</sup>. De-glycopeptides  
283 were searched with the Andromeda search engine<sup>14</sup> in MaxQuant.<sup>15</sup> Cleavage specificity was set to fully tryptic  
284 with 2 missed cleavage allowed and a minimum length of 7 residues, oxidation of methionine and deamidation  
285 of asparagine were set as a variable modification, and carbamidomethylation of cysteine was set as a fixed  
286 modification. Defaults were used for the remaining settings, including PSM and protein FDR thresholds of 0.01;  
287 and 20 ppm, 4.5 ppm, and 20 ppm for first search MS1 tolerance, main search MS1 tolerance, and MS2  
288 product ion tolerance, respectively. The Deamidation Sites table was used for further data analysis, randomly  
289 chosen spectra were spot-checked for identification accuracy using IPSA to ensure data quality, and  
290 deamidated peptides were marked as either “True” or “False” for whether they contained the N-glycosylation  
291 sequon, N-X-S/T, where X is any residue but proline. This Deamidation Sites table file was then uploaded into  
292 Perseus and further filtered to remove 1) potential contaminants and reverse hits, 2) peptides that did not  
293 contain the N-glycosylation sequon, 3) sites with less than 0.5 localization probability, and 4) identifications that

294 had more than three missing values. Missing values for the remaining identifications were imputed from a  
 295 normal distribution with width 0.3 and downshift value of 1.8 (i.e., default values).  
 296  
 297

### 298 **Statistical analysis**

299 All statistical hypothesis tests were performed using either a hierarchical permutation test<sup>16</sup> (20,000 resamples  
 300 for n=3 treatments, 70,000 for n=4, 200,000 for n>4) or a Welch's t-test. Code is available at [github.com/rishi-](https://github.com/rishikulkarni/hierarch)  
 301 [kulkarni/hierarch](https://github.com/rishikulkarni/hierarch).  
 302

### 303 **DNA oligonucleotides**

Usage	DNA Sequence
mNeu3 KO sgRNA (FWD)	CACCGGAGAGGTGCCAGATTGTGTG
mNeu3 KO sgRNA (REV)	AAACCACACAATCTGGCACCTCTCC
murine safe-targeting sgRNA (FWD)	CACCGGAAATCCTTACCTAAGACAA
murine safe-targeting sgRNA (REV)	AAACTTGTCTTAGGTAAGGATTTCC
mNeu3 KO PCR (FWD)	GGGCCTTCAAGATTCTGTCCATTT
mNeu3 KO PCR (REV)	GTGCCATGTGACTCCAAAGTCATC
mNeu3 KO SEQ	TTTCAATGTCCTATATTGTTTGAAAAAGAAGCTG
mNeu3 HDR sgRNA (FWD)	CACCGCGACTAAAGCCAAATCAAGA
mNeu3 HDR sgRNA (REV)	AAACTCTTGATTTGGCTTTAGTCGC
mNeu3 HDR PCR (FWD)	TCCCCGACCTGCAGCCCAGCT
mNeu3 HDR PCR (REV)	TGGAGAGGACTTTCCAAG
GAPDH qPCR (FWD)	CCCATCACCATCTTCCAGGAGC
GAPDH qPCR (REV)	CCAGTGAGCTTCCCGTTCAGC
mNEU1 qPCR (FWD)	TTCATCGCCATGAGGAGGTCCA
mNEU1 qPCR (REV)	AAAGGGAATGCCGCTCACTCCA
mNEU3 qPCR (FWD)	CTCAGTCAGAGATGAGGATGCT
mNEU3 qPCR (REV)	GTGAGACATAGTAGGCATAGGC
mNEU4 qPCR (FWD)	AGGAGAACGGTGCTCTTCCAGA
mNEU4 qPCR (REV)	GTTCTTGCCAGTGCGGATTTGC

304  
 305

### **DNA gene sequences and gBlocks**


Gene	DNA Sequence
NEU3 HOM1	TCCCCGACCTGCAGCCCAGCTCTACACTCGGGAAGGCTGATCATCCCC GCCTATGCCTACTATGTCTCACGTTGGTTTCTCTGCTTTGCGTGTTTCAGTCAAG CCCCATTCCCTGATGATCTACAGTGATGACTTTGGAGTCACATGGCACCATGGC AAGTTCATTGAGCCCCAGGTGACAGGGGAGTGCCAAGTGGCCGAAGTGGCTG GGACGGCTGGTAACCCTGTGCTCTACTGCAGTGCCCGAACACCAAGCCGATTT CGAGCAGAGGCTTTTAGTACTGATAGTGGTGGCTGCTTTCAGAAGCCAACCCT GAACCCACAACCTCCATGAGCCTCGAACCGGCTGCCAAGGTAGTGTAGTGAGCT TCCGGCCTTTGAAGATGCCAAATACCTATCAAGACTCAATTGGCAAAGGTGCTC CCGCTACTCAGAAGTGCCCTCTGCTGGACAGTCCTCTGGAGGTGGAGAAAGGA GCTGAAACACCATCAGCAACATGGCTCTTGTACTCACATCCAACCTAGCAAGAGG AAGAGGATTAACCTAGGCATCTACTACAACCGGAACCCCTTGGAGGTGAACTG



	CTGGTCCC GCCCGTGGATCTTGAACCGTGGGCCCAGTGGCTACTCTGATCTGG CTGTTGTGGAAGAACAGGACTTGGTGGCGTGTGTTGTTGAGTGTGGGGAGAAG AATGAGTATGAGCGGATTGACTTCTGTCTGTTTTTCAGACCATGAGGTCCTGAGC TGTGAAGACTGTACCAGCCCTAGTAGCGACGGGAGCGGAGGAGGTTCCGG
NEU3 HOM2	AGTTCTTCTGATTCGAACATCGATGAGTGAGGCCAGCTTCCCACAGAA AGGAATGGCAGCTACAGCCAGGGTAACAGAGGTCTCTGATGTCTAGAGAAAAC TCTAAAACTAATAATCTGCTCCTTGAATTTTTTCACTTTTCCCTTCAATGAGCAT GGTGA AAATTGTGCCATATCTTACATAACGAGGCTCTTGA ACTGGGAGTTTCAA TCTCTTCTCTTCCATTAAAAGGAGAGGCCATGTGCTCGCTTCGCGTTTCGACAA AGCCTGGATTCTGATCTTGAGTGGAAAGCCACAGGCTTGTCTTTTCCAATGGTTC ACTGCTCACCTGAGTATTAGGTGATGTGTAGGTGCCTTGGCCAGAAGAAAGAT CTGTGTTGTTGTATTTTTTAAATTTATTTACTATATGTAAGTACACTGCAG CTGTCTTCAGACACACCAGAAGAGGGCGTCAGATCTCATTAGAGATGGTTGTG AGCCACCATGTGGTTGCTGGGATTTGAACTCAGGACCTTCAGAAGAGCAGTCA GTGCTCTTA ACTACTGAGCCATCTCTCAAGCCCCGCATTGCTGTATTTTTAATAA GAAAAATGCCCTTATCCTTCCAATAATGCCTGGAGCTGTACAAATTCTCTGTCTT AGAAGACTTGAGAAAGCAGAACTGTAAGGTCAGATGCTTTCTCCAGCCTTGATG CTGTGTTCCACCTTCCCTTCTCATCCAGAAAACAGTTACTAGGGAGAAAATGA GAAACCCATGCCAGCTGCCTTGGAAAGTCCTCTCCA
mNEU3 wt	ATGGAAGAGGTGCCTCCTTATAGCCTTAGTAGCACCCCTGTTCCAGCAAG AAGAGCAGAGTGGAGTAACTTATAGAATCCCGGCTCTTCTCTATCTCCCCCTA CGCATACATTTTTGGCATTGCGGAAAAAAGGACATCCGTCCGGGATGAAGAT GCGGCGTGTCTCGTGTGAGGAGAGGACTCATGAAAGGTCGCAGTGTTCAGTG GGGGCCACAGCGCCTCTTGATGGAAGCTACGCTTCTGGGCACAGGACAATG AACCCGTGCCCGGTATGGGAAAAGAACACTGGAAGAGTTTACTTGTTCTTCATC TGCGTGAGGGGGCACGTCACAGAGCGGTGCCAGATAGTCTGGGGAAAGAATG CGGCGCGCCTTTGTTTTTGTGCAGTGAAGATGCGGGATGCTCCTGGGGTGAG GTGAAGGATTTGACCGAAGAAGTCATTGGCTCTGAGGTGAAAAGATGGGCAAC CTTCGCTGTCGGACCAGGACACGGGATACAGCTGCATTACAGGCCGGCTGATCA TTCCGGCTTATGCCTACTATGTCTCCCGCTGTTTCTTTGTTTTGCATGCAGCG TCAAACCGCACTCCCTCATGATACTCCGACGATTTCCGGGGTGACATGGCATC ACGGAAGTTTCAATTGAACCTCAAGTCACCGGTGAATGCCAGGTGCGGGAGGTG GCAGGTACAGCCGGCAACCCGGTCTTTATTGCAGCGCTCGGACCCCGTCCC GCTTTAGAGCCGAAGCCTTTAGTACAGATTCTGGCGGCTGCTTCCAAAAACCG ACTCTCAACCCTCAACTCCACGAACCTAGAACAGTTGCCAAGGAAGCGTTGT GAGCTTCCGGCCGTTGAAGATGCCAAACACATATCAAGACTCTATCGGTAAGG GGGCGCCTGCGACGCAAAAGTGTCCACTCCTCGACAGCCCACTGGAGGTGCGA GAAAGGCGCGGAAACCCCTTCCGCGACGTGGTTGCTGTATTCACATCCCACTA GCAAGAGGAAGAGAATTAACCTGGGGATTTACTACAATCGCAACCCGCTGGAG GTTAACTGCTGGAGTCGGCCGTGGATCCTTAACCGGGTCCATCAGGCTACAG CGACCTGGCGGTAGTTGAGGAGCAGGATTTGGTGGCTTGCCTCTTTGAGTGCG GGGAGAAGAACGAATATGAGCGGATCGATTTCTGTTTGTGTTTCTGATCACGAAG TATTGTCATGTGAAGATTGTA CTTCCCGTCTTCAGACGGGAGCGGAGGAGGT TCCG Gtggagggtggttctggagattacaaggatgacgacgataagggcgattacaaggatgacgacgataagg gagattacaaggatgacgacgataag
mNEU3 Y369F	ATGGAAGAGGTGCCTCCTTATAGCCTTAGTAGCACCCCTGTTCCAGCAAG AAGAGCAGAGTGGAGTAACTTATAGAATCCCGGCTCTTCTCTATCTCCCCCTA

CGCATACATTTTTGGCATTGCGGAAAAAAGGACATCCGTCCGGGATGAAGAT  
GCGGCGTGTCTCGTGTGAGGAGAGGACTCATGAAAGGTTCGCAGTGTTCAGTG  
GGGGCCACAGCGCCTCTTGATGGAAGCTACGCTTCCTGGGCACAGGACAATG  
AACCCGTGCCCGGTATGGGAAAAGAACACTGGAAGAGTTTACTTGTTCATC  
TGCGTGAGGGGGCACGTCACAGAGCGGTGCCAGATAGTCTGGGGAAAGAATG  
CGGCGCGCCTTTGTTTTTTGTGCAGTGAAGATGCGGGATGCTCCTGGGGTGAG  
GTGAAGGATTTGACCGAAGAAGTCATTGGCTCTGAGGTGAAAAGATGGGCAAC  
CTTCGCTGTCGGACCAGGACACGGGATACAGCTGCATTACAGGCCGGCTGATCA  
TTCCGGCTTATGCCTACTATGTCTCCCGCTGGTTCCCTTTGTTTTGCATGCAGCG  
TCAAACCGCACTCCCTCATGATACTCCGACGATTCGGGGTGACATGGC  
ACGAAAGTTCATTGAACCTCAAGTCACCGGTGAATGCCAGGTTCGCGGAGGTG  
GCAGGTACAGCCGGCAACCCGGTCTTTATTGCAGCGCTCGGACCCCGTCCC  
GCTTTAGAGCCGAAGCCTTTAGTACAGATTCTGGCGGCTGCTTCCAAAACCG  
ACTCTCAACCCTCAACTCCACGAACCTAGAACAGGTTGCCAAGGAAGCGTTGT  
GAGCTTCCGGCCGTTGAAGATGCCAAACACATATCAAGACTCTATCGGTAAGG  
GGGCGCCTGCGACGCAAAAGTGTCCACTCCTCGACAGCCCACTGGAGGTGCA  
GAAAGGCGCGGAAACCCCTTCCGCGACGTGGTTGCTGTATTCACATCCCACTA  
GCAAGAGGAAGAGAATTAACCTGGGGATTTACTACAATCGCAACCCGCTGGAG  
GTTAACTGCTGGAGTCGGCCGTGGATCCTTAACCGGGTCCATCAGGCTTTAG  
CGACCTGGCGGTAGTTGAGGAGCAGGATTTGGTGGCTTGCCTCTTTGAGTGCG  
GGGAGAAGAACGAATATGAGCGGATCGATTTCTGTTTGTCTGATCACGAAG  
TATTGTCATGTGAAGATTGTACTTCCCCGTCTCAGACGGGAGCGGAGGAGGT  
TCCGtggagggtggtctggagattacaaggatgacgacgataagggcgattacaaggatgacgacgataagg  
gagattacaaggatgacgacgataag


306



307


308 **Figure S1. Tracking of Indels by Decomposition (TIDE) analysis of *NEU3* KO BV-2 microglia.** To confirm  
 309 knock-out of the *NEU3* gene in murine BV-2 microglia, CRISPR-Cas9 edited cells were subjected to two weeks  
 310 of selection before genomic DNA was harvested and the cut region was amplified and sequenced. TIDE [ref]  
 311 deconvolutes the possible changes from CRISPR-based editing to provide gene-level editing quantitation.

312



313

314 **Figure S2. Neu3 desialylates microglia in cis but is not necessary for inflammatory activity. (A,B)** Wild-  
 315 type or *NEU3* knock-out (*NEU3* KO) BV-2 microglia were stimulated with LPS for 24 h, with or without deoxy-  
 316 2,3-anhydroneuraminic acid (DANA). **(A)** Quantification of TNF- $\alpha$  secretion by LPS-treated WT and *NEU3* KO  
 317 microglia by flow cytometry reveals that *NEU3* KO microglia are capable of activating in response to LPS (WT:  
 318 -LPS vs. +LPS,  $p=0.002$ ; -LPS vs. +LPS+DANA,  $p=0.039$ ; +LPS vs. +LPS+DANA,  $p=0.0003$ ) (*NEU3* KO: -LPS  
 319 vs. +LPS,  $p=0.02$ ; -LPS vs. +LPS+DANA,  $p=0.001$ ; +LPS vs. +LPS+DANA,  $p=0.055$ ).  $n=3$  wells/condition.  
 320 Hypothesis tests performed with Welch's *t*-test. **(B, C)** Periodate labeling of activated vs. resting WT and *NEU3*  
 321 KO microglia (WT,  $p=0.0383$ ; *NEU3* KO,  $p=0.5073$ ).  $n=3$  wells/condition, 10 microglia/well. All hypothesis tests  
 322 performed with hierarchical permutation test.



323

324

325

326


327

328

329

330

**Figure S3. Surface or whole-lysate proteomics of enriched extracellular vesicles does not identify Neu3.** Extracellular vesicles from BV-2 microglia were enriched and either lysed (whole-lysate) or subjected to cell surface biotinylation using sulfo-NHS-biotin, followed by lysis and biotin/streptavidin enrichment as described in the materials and methods. Data were quantitated by label-free quantitation. Known surface proteins (blue diamonds) and exosomal proteins (red squares), based on Uniprot GOCC annotation, are labeled.



331

332

333

334

335


336

337


338

**Figure S4. Homology-directed recombination (HDR) produces endogenous Neu3 with a 3xFLAG tag.** (A,B) BV-2 microglia were co-transfected with a CRISPR-Cas9 based cutting plasmid and a donor plasmid for HDR to insert the coding sequence for a 3xFLAG tag at the C-terminus of the endogenous *NEU3* gene. (A) PCR of the *NEU3* gene shows increased amplicon size in a polyclonal population of transfectants, congruent with tag incorporation. (B) Western-blot of whole-cell lysates from parental BV-2 or HDR-transfectants shows a noticeable and quantifiable band in the transfectants at the expected molecular weight of mNeu3.


A




B



340 **Figure S5. LPS-stimulation increases a population of Neu3+ extracellular vesicles in BV-2 microglia.**  
 341 After exposure of BV-2 microglia with endogenously FLAG-tagged Neu3 to vehicle or LPS, EVs were captured  
 342 on anti-mCD81 or anti-mCD9 coupled beads, labeled with fluorophore-coupled anti-FLAG or anti-mCD63, and  
 343 analyzed by flow cytometry. **(A)** Representative experimental scheme. **(B)** Representative pseudocolor dot  
 344 plots from bead-capture experiments in **Figure 2A**.




345  
 346 **Figure S6. HeLa cells overexpress FLAG-tagged mNeu3 upon transient transfection.** HeLa cells were  
 347 transfected with plasmid encoding either wild-type mNeu3 or a loss-of-function mutant (Y396F) with a C-  
 348 terminal FLAG tag. Whole cells were lysed and lysates were separated by SDS-PAGE, transferred to  
 349 nitrocellulose, and probed by Western blot with IR-dye conjugated anti-FLAG or anti-GAPDH antibodies.



350  
 351 **Figure S7. Neu3 on HeLa-derived extracellular vesicles is sufficient to desialylate neurons in culture.**  
 352 Primary mouse hippocampal neurons were treated with conditioned media from NEU3-overexpressing HeLa  
 353 cells in the presence or absence of deoxy-2,3-anhydroneuraminic acid (DANA). Cell surface sialic acid levels  
 354 were visualized by periodate labeling. Representative images **(A)** and quantification of fluorescence **(B)** reveal  
 355 that Neu3 from HeLa-derived extracellular vesicles significantly reduce surface sialic acids ( $p=0.028$ ) in a  
 356 sialidase-inhibitor dependent manner.  $n=3$  coverslips/condition, 25 cells/condition.

357





358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

**Figure S8. Neu3 on HeLa-derived extracellular vesicles do not produce significant change in firing rate of neurons.** Neurons were labeled with the voltage-sensitive dye BeRST1 and treated with extracellular-vesicle enriched media from either microglia or Neu3 over-expressing cells. Neuronal firing rates and network connectivity were analyzed by fluorescence microscopy. **(A,B)** BeRST1 is a membrane-localizing voltage-sensitive fluorophore that undergoes a dramatic increase in fluorescence intensity in response to changes in membrane potential, i.e. upon the depolarization of firing neurons. Representative brightfield and BeRST1 fluorescence of a single field of view **(A)** and voltage traces of each neuron in a single field of view **(B)** contain both subthreshold activity and spiking activity. **(C)** BV-2 microglia treated with or without LPS and with or without GW4869. The EVs from the conditioned media were enriched and neurons were treated with EV-enriched media, and neuronal activity was measured by voltage imaging with BeRST1. Firing rates of neurons treated with BV-2 EV-enriched media reveal 1.7 Hz decrease in +LPS condition compared to -LPS condition ( $p=0.048$ ). The effect is partially rescued by inhibition of EV production with GW4869 (+LPS vs. +LPS+GW4869,  $p=0.062$ ). **(D)** As in **(C)**, but using conditioned media from HeLa cells overexpressing either wild-type or loss-of-function (Y369F) Neu3. Firing rates of neurons treated with EV-enriched media of NEU3-overexpressing HeLa cells reveal no significant changes between functional NEU3 and a loss-of-function point mutant (WT: -0.26 Hz,  $p=0.58$ ; Y369F: -0.14 Hz,  $p=0.65$ ). For **(C)**:  $n=4$  coverslips/condition, 168 neurons total. For **(D)**:  $n=3$  coverslips/condition, 331 total neurons. All hypothesis testing was performed by hierarchical permutation tests.

379 **Supporting Information References**

- 380 (1) Sanjana, N. E.; Shalem, O.; Zhang, F. Improved Vectors and Genome-Wide Libraries for CRISPR  
 381 Screening IPipet: Sample Handling Using a Tablet. *Nat. Publ. Gr.* **2014**, *11* (8), 783–784.  
 382 <https://doi.org/10.1038/nmeth.3047>.
- 383 (2) Haney, M. S.; Bohlen, C. J.; Morgens, D. W.; Ousey, J. A.; Barkal, A. A.; Tsui, C. K.; Ego, B. K.; Levin,  
 384 R.; Kamber, R. A.; Collins, H.; et al. Identification of Phagocytosis Regulators Using Magnetic Genome-  
 385 Wide CRISPR Screens. *Nat. Genet.* **2018**, *50* (12), 1716–1727. <https://doi.org/10.1038/s41588-018-0254-1>.  
 386
- 387 (3) Pronobis, M. I.; Deutch, N.; Peifer, M. The Miraprep: A Protocol That Uses a Miniprep Kit and Provides  
 388 Maxiprep Yields. **2016**, No. Table 1, 1–12. <https://doi.org/10.1371/journal.pone.0160509>.
- 389 (4) Brinkman, E. K.; van Steensel, B. Rapid Quantitative Evaluation of CRISPR Genome Editing by TIDE  
 390 and TIDER. In *CRISPR Gene Editing: Methods and Protocols*; 2019; pp 29–44.
- 391 (5) Savic, D.; Partridge, E. C.; Newberry, K. M.; Smith, S. B.; Meadows, S. K.; Roberts, B. S.; Mackiewicz,  
 392 M.; Mendenhall, E. M.; Myers, R. M. CETCh-Seq: CRISPR Epitope Tagging ChIP-Seq of DNA-Binding  
 393 Proteins. *Genome Res.* **2015**, 1581–1589. <https://doi.org/10.1101/gr.193540.115>.
- 394 (6) Wei, W.; Riley, N. M.; Yang, A. C.; Kim, J. T.; Terrell, S. M.; Li, V. L.; Garcia-Contreras, M.; Bertozzi, C.  
 395 R.; Long, J. Z. Cell Type-Selective Secretome Profiling in Vivo. *Nat. Chem. Biol.* **2021**, *17* (3), 326–334.  
 396 <https://doi.org/10.1038/s41589-020-00698-y>.
- 397 (7) HaileMariam, M.; Eguez, R. V.; Singh, H.; Bekele, S.; Ameni, G.; Pieper, R.; Yu, Y. S-Trap, an Ultrafast  
 398 Sample-Preparation Approach for Shotgun Proteomics. *J. Proteome Res.* **2018**, *17* (9), 2917–2924.  
 399 <https://doi.org/10.1021/acs.jproteome.8b00505>.
- 400 (8) Bausch-Fluck, D.; Hofmann, A.; Bock, T.; Frei, A. P.; Cerciello, F.; Jacobs, A.; Moest, H.; Omasits, U.;  
 401 Gundry, R. L.; Yoon, C.; et al. A Mass Spectrometric-Derived Cell Surface Protein Atlas. *PLoS One*  
 402 **2015**, *10* (4), 1–22. <https://doi.org/10.1371/journal.pone.0121314>.
- 403 (9) Leung, K. K.; Wilson, G. M.; Kirkemo, L. L.; Riley, N. M.; Coon, J. J.; Wells, J. A. Broad and Thematic  
 404 Remodeling of the Surfaceome and Glycoproteome on Isogenic Cells Transformed with Driving  
 405 Proliferative Oncogenes. *Proc. Natl. Acad. Sci. U. S. A.* **2020**, *117* (14), 7764–7775.  
 406 <https://doi.org/10.1073/pnas.1917947117>.
- 407 (10) Wenger, C. D.; Coon, J. J. A Proteomics Search Algorithm Specifically Designed for High-Resolution  
 408 Tandem Mass Spectra. *J. Proteome Res.* **2013**, *12* (3), 1377–1386. <https://doi.org/10.1021/pr301024c>.
- 409 (11) Solntsev, S. K.; Shortreed, M. R.; Frey, B. L.; Smith, L. M. Enhanced Global Post-Translational  
 410 Modification Discovery with MetaMorpheus. *J. Proteome Res.* **2018**, *17* (5), 1844–1851.  
 411 <https://doi.org/10.1021/acs.jproteome.7b00873>.
- 412 (12) Bateman, A. UniProt: A Worldwide Hub of Protein Knowledge. *Nucleic Acids Res.* **2019**, *47* (D1), D506–  
 413 D515. <https://doi.org/10.1093/nar/gky1049>.
- 414 (13) Millikin, R. J.; Solntsev, S. K.; Shortreed, M. R.; Smith, L. M. Ultrafast Peptide Label-Free Quantification  
 415 with FlashLFQ. *J. Proteome Res.* **2018**, *17* (1), 386–391.  
 416 <https://doi.org/10.1021/acs.jproteome.7b00608>.
- 417 (14) Cox, J.; Neuhauser, N.; Michalski, A.; Scheltema, R. A.; Olsen, J. V.; Mann, M. Andromeda: A Peptide  
 418 Search Engine Integrated into the MaxQuant Environment. *J. Proteome Res.* **2011**, *10* (4), 1794–1805.  
 419 <https://doi.org/10.1021/pr101065j>.
- 420 (15) Tyanova, S.; Temu, T.; Cox, J. The MaxQuant Computational Platform for Mass Spectrometry-Based  
 421 Shotgun Proteomics. *Nat. Protoc.* **2016**, *11* (12), 2301–2319. <https://doi.org/10.1038/nprot.2016.136>.
- 422 (16) Kulkarni, R. U.; Wang, C. L.; Bertozzi, C. R. Analyzing Nested Experimental Designs—A User-Friendly



423  
424  
425  
426  
427  
428  
429  
430

Resampling Method to Determine Experimental Significance. *PLoS Comput. Biol.* **2022**, *18* (5), 1–26.  
<https://doi.org/10.1371/journal.pcbi.1010061>.